Exelixis Reorganizes R&D And Cuts Its Workforce By 40 Percent
The biotech hopes to advance three late-stage compounds and others into development, but the overall tally will be reduced for the foreseeable future.
The biotech hopes to advance three late-stage compounds and others into development, but the overall tally will be reduced for the foreseeable future.